v3.26.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss     $ (1,752,989) $ (6,572,723)  
Net income (loss) from discontinued operations     2,591,239 (1,029,656)  
Net loss from continuing operations     (4,344,228) (5,543,067)  
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities:          
Allowance for expected credit losses     872,122 246,883  
Depreciation and amortization     1,286,804 1,289,747  
Stock-based compensation     643,861 764,036  
Amortization of right-of-use assets     4,959 41,815  
Loss on issuance of SEPA     145,174 0  
Loss on extinguishment of loan     0 126,125 $ (42)
Loss on issuance of financial instruments $ 0 $ 0 0 138,020  
Change in fair value of financial instruments     32,101 1,416,296  
Gain on extinguishment of financial liabilities     (367,809) 0  
Changes in operating assets and liabilities:          
Accounts receivable     (861,915) (707,666)  
Due from related party     (10,859) 290,534  
Prepaids and other current assets     (124,520) 53,076  
Accounts payable and accrued liabilities     224,968 711,043  
Operating lease liabilities     (4,959) (34,324)  
Net cash used in operating activities - continuing operations     (2,504,301) (1,207,482)  
Net cash (used in) provided by operating activities - discontinued operations     (1,121,615) 442,388  
Net cash used in operating activities     (3,625,916) (765,094)  
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of long-term investments     (100,000) 0  
Net cash used in investing activities- continuing operations     (100,000) 0  
Net cash used in investing activities- discontinued operations     (28,752) (15,466)  
Net cash used in investing activities     (128,752) (15,466)  
CASH FLOWS FROM FINANCING ACTIVITIES:          
Repayment of notes payable     (780,290) 0  
Payment to shareholder     0 (10,000)  
Proceeds from issuance of common stock     0 90,634  
Proceeds from notes issued during the period     176,750 726,237  
Proceeds from factoring payable     0 55,665  
Proceeds from pre-funded warrants, net of issuance costs     984 0  
Proceeds from convertible notes issued during the period     750,000 0  
Payments on Encompass acquisition liability     (50,000) (44)  
Payments on financing lease liability     (591,118) (25,000)  
Payments on line of credit     (348,952) 0  
Net cash (used in) provided by financing activities - continuing operations     (842,626) 837,492  
Net cash used in financing activities - discontinued operations     0 (91,452)  
Net cash (used in) provided by financing activities     (842,626) 746,040  
NET CHANGE IN CASH     (4,597,294) (34,520)  
Cash, Beginning of Period     5,051,445 326,115 326,115
CASH, END OF THE PERIOD $ 454,151 $ 291,595 454,151 291,595 $ 5,051,445
Supplemental disclosure of cash flow information:          
Cash paid for interest expense     418,689 135,205  
Non-cash investing and financing activities:          
Common stock issued on conversion of notes payable     299,348 0  
Common stock issued on conversion of Quantum note     521,721 0  
Common stock issued to settle directors’ compensation payable     60,762 0  
Common stock issued to settle executives’ compensation payable     555,457 0  
Common stock issued to settle employees and consultants’ compensation payable     776,842 0  
Common stock issued as consideration for investment in GoMyRX Inc.     649,800 0  
Common and preferred stock issued to settle accounts payable     $ 1,573,800 $ 0